|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
DECEMBER 29, 2003
Faster Pulse At Esperion  Esperion Therapeutics (ESPR
) rocketed from 17 a share on Nov. 4 to 26 on Nov. 6, when it disclosed that its intravenous drug ETC-216, designed to prevent further heart attacks in people who have just had one, was "safe and well tolerated" in clinical trials. The stock has since eased to 22.30 but may zip up again, says Mark Monane of in-vestment firm Needham. Pfizer (PFE
), Genentech, (DNA
) or Aventis (AVE
) could strike a deal for any of Esperion's four cardiovascular drugs now in trials, he says.
Pfizer makes Lipitor, the top drug for "bad" cholesterol. Monane says Esperion's products would widen Pfizer's market reach. For instance, Esperion's ETC-1001 boosts good cholesterol and reduces the bad. Recent trials on ETC-1001 show it "inhibits progression of atherosclerosis," says Matthew Geller of CIBC World Markets, who rates the stock a buy. Esperion has three intravenous products, including ETC-216, for which Pfizer has the right of first refusal. Another is ETC-588 for carotid atherosclerosis. Needham's Monane says a deal to co-develop and co-market the drugs may come in three months. A product launch isn't expected until 2007, says Monane, who sees Esperion in the black by 2008. His price target of 25 doesn't include the impact of a deal. CIBC's Geller's target is 31, based on 2008 earnings of $1.72 a share. Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2003, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version
